The Patient

Sarah, 34.
More than a statistic.

Diagnosed with Stage II Triple-Negative Breast Cancer.
The guidelines suggest a standard regimen. But Sarah's biology is unique. To find the cure hidden in her cells, we don't just look at one piece of the puzzle—we merge them all.

Multimodal Data Ingestion

image Pathology

add

blur_on Omics

add

clinical_notes Clinical

arrow_forward

Enso Engine

Sarah M.

TNBC, Stage II

High Risk

Biopsy ID BX-9920-A

Treatment Plan Pending Analysis...

The Analysis

Enso processes the H&E slide, extracts patch embeddings, and integrates transcriptomic signals to map Sarah's disease in high-dimensional space.

grid_on Patch Extraction

Breast malignant triple-negative pathology slide

AI Finding: Immune-Excluded Phenotype detected. High fibroblast density isolating tumor nests.

dataset Key Gene Signatures

RNA-Seq Analysis

Gene

Function

Expression

SLC7A2

Arginine transporter, associated with macrophage modulation.

PLXND1

Plexin D1, guides cell migration and angiogenesis.

MTMR7

Phosphatase involved in membrane trafficking.

CASP10

Apoptosis initiator caspase.

Patient Embedding Space

UMAP Projection of Multimodal Embeddings

Responders (Trial A)

Non-Responders

Sarah

Sarah (Current)

Predicted Non-Responder

lightbulb

Insight

Sarah clusters with patients who failed SoC but responded to Anti-CAF therapy.

The Outcome Comparison

description Standard Guidelines

Protocol 12b

Neoadjuvant Chemotherapy + Pembrolizumab

Predicted Response (pCR) 22%

Risk of Toxicity High

Recommended

radio_button_unchecked Enso-Guided Strategy

Protocol 12b + Anti-CAF

Targeting the fibroblast shell to enable immune infiltration.

Predicted Response (pCR) 68%

trending_up 3x Improvement

Sarah, 34. More than a statistic.